Open AccessCost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Author(s) -
Amanda Harrington,
Edward P. Armstrong,
Paul E. Nolan,
Daniel C. Malone
Publication year - 2013
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.111.000402
Subject(s) - apixaban , rivaroxaban , dabigatran , medicine , warfarin , atrial fibrillation , stroke (engine) , anesthesia , cost effectiveness , mechanical engineering , risk analysis (engineering) , engineering
To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom